Want to see AMRN full AI Analyst Report?
Top Page
Amarin
(NASDAQ:AMRN)
Select Model
Select Model
Rating:54Neutral
Price Target:
$14.50
▲(7.01% Upside)
Action:Reiterated
Date:07/30/26
AMRN’s score is driven primarily by mixed fundamentals: a strong, low-leverage balance sheet and improved cash generation are offset by contracting revenue and continued operating losses. Technicals are weak with the stock trading below key moving averages, while the latest earnings call adds moderate support through positive cash-flow guidance and cost reductions but acknowledges ongoing revenue and pricing/reimbursement headwinds. Corporate governance outcomes add a smaller negative overhang due to incentive and cash-compensation constraints.
Positive Factors
Low leverage, strong balance sheet
Very low debt and sizable equity (~$444M) provide durable financial flexibility to fund commercialization, partnerships, and operations without near-term refinancing risk. This buffer supports execution through revenue volatility and limits solvency risk while management pursues growth or M&A.
Negative Factors
Multi-year revenue contraction
Persistent revenue declines reduce operating leverage and make fixed-cost absorption harder, pressuring gross and operating margins over time. Continued top-line erosion undermines sustainable cash generation and constrains reinvestment in sales, market access, and international launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage, strong balance sheet
Very low debt and sizable equity (~$444M) provide durable financial flexibility to fund commercialization, partnerships, and operations without near-term refinancing risk. This buffer supports execution through revenue volatility and limits solvency risk while management pursues growth or M&A.
Read all positive factors
Amarin (AMRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$297.18M
Dividend YieldN/A
Average Volume (3M)71.00K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth-15.63%
EPS Growth74.20%
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.43
Shares Outstanding21,122,835
10 Day Avg. Volume100,478
30 Day Avg. Volume71,000
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)1.36
P/FCF Ratio42.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$177.79M
Amarin Business Overview & Revenue Model
Company Description
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Ger...
How the Company Makes Money
Amarin makes money primarily by selling its prescription drug icosapent ethyl under the brand VASCEPA (U.S.) and VAZKEPA (in certain non-U.S. markets). Revenue is generated from product sales to pharmaceutical wholesalers, distributors, and specia...
Amarin Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call presented a mix of constructive operational and financial improvements alongside transitional revenue headwinds. Amarin emphasized strong international volume growth (59% global, 69% Europe under Recordati), completion of restructuring with material cost savings, improved cash generation and a stronger balance sheet. At the same time, reported revenue declined year-over-year due to a prior-year upfront payment and the shift to a partnered European model, COGS increased 22%, and certain geographies remain early with reimbursement timing risks. Management's commentary was optimistic about the trajectory, highlighting sequential European revenue gains, narrowing operating losses and ongoing positive cash flow.Positive Updates
Strong international volume growth
In-market demand across Amarin's combined global partner network rose 59% year-over-year in cumulative volume as of June 30, 2026, driven primarily by the Recordati partnership and other international partners.
Negative Updates
Reported net revenue decline year-over-year
Total net revenue in Q2 2026 was $42.2 million versus $72.7 million in Q2 2025. The prior-year period included a $25 million upfront payment related to the Recordati transaction, which explains much of the YoY comparison, but the headline revenue decline remains material.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong international volume growth
In-market demand across Amarin's combined global partner network rose 59% year-over-year in cumulative volume as of June 30, 2026, driven primarily by the Recordati partnership and other international partners.
Read all positive updates
Company Guidance
Management's guidance centered on expecting positive cash flow for full-year 2026, maintaining key payer exclusivity through year-end 2026, and U.S. volumes remaining stable through 2026; that outlook is supported by Q2 metrics including $314.6M cash and investments (up $12M from YE‑2025), $7M of operating cash flow in Q2 (third consecutive quarter), $439M working capital, inventory declines of $19.5M QoQ and $31.8M YTD, completion of restructuring delivering ~ $70M of annual cost savings and a 59% ($39.3M) reduction in operating expenses to $27.0M (SG&A $22.2M, down 43%), a narrowed operating loss of $12M (from $16M), commercial traction with VASCEPA U.S. share at 48% (up from 43%), branded scripts +14% YoY, U.S. IPE market +3% YoY, and accelerating international demand (global in‑market demand +59% cumulative YoY; Europe +69% Q2 YoY) as VASCEPA/VAZKEPA are now available in 22 countries (VAZKEPA commercialized in 11 European countries) under partnerships including Recordati (59‑country license).Amarin Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
74
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 186.16M | 213.65M | 228.61M | 306.91M | 369.19M | 583.19M |
| Gross Profit | 77.40M | 120.87M | 81.38M | 165.54M | 242.48M | 461.86M |
| EBITDA | -19.69M | -33.01M | -74.18M | -50.70M | -100.69M | 14.28M |
| Net Income | -27.12M | -38.80M | -82.18M | -59.11M | -105.80M | 7.73M |
Balance Sheet | ||||||
| Total Assets | 624.36M | 670.77M | 685.35M | 831.68M | 886.18M | 1.07B |
| Cash, Cash Equivalents and Short-Term Investments | 314.65M | 302.79M | 294.22M | 320.66M | 309.36M | 454.13M |
| Total Debt | 5.25M | 12.16M | 7.72M | 8.74M | 10.02M | 8.58M |
| Total Liabilities | 180.75M | 211.49M | 199.17M | 279.59M | 290.85M | 400.97M |
| Stockholders Equity | 443.62M | 459.28M | 486.18M | 552.10M | 595.33M | 667.10M |
Cash Flow | ||||||
| Free Cash Flow | 49.17M | 6.74M | -31.02M | 6.88M | -179.98M | -66.53M |
| Operating Cash Flow | 49.17M | 6.74M | -31.03M | 6.91M | -179.98M | -66.53M |
| Investing Cash Flow | -17.99M | 8.85M | -45.98M | -25.62M | 175.18M | 104.09M |
| Financing Cash Flow | -2.12M | -2.04M | -1.44M | 230.89K | -378.77K | -5.07M |
Amarin Technical Analysis
Negative
13.55
Price Trends
14.76
Negative
14.64
Negative
14.91
Negative
Market Momentum
-0.15
Negative
43.96
Neutral
36.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRN, the sentiment is Negative. The current price of 13.55 is below the 20-day moving average (MA) of 14.04, below the 50-day MA of 14.76, and below the 200-day MA of 14.91, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 43.96 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMRN.
Amarin Risk Analysis
Amarin disclosed 65 risk factors in its most recent earnings report. Amarin reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amarin Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $297.18M | -9.85 | -5.99% | ― | -15.63% | 74.20% | |
52 Neutral | $240.97M | -8.08 | -93.74% | ― | 7.52% | 35.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $243.81M | -2.71 | -59.27% | ― | -100.00% | -49.28% | |
45 Neutral | $424.02M | -2.33 | 12.30% | ― | 55.22% | 2.13% | |
41 Neutral | $68.49M | -1.21 | -61.55% | ― | ― | -59.74% |
* Healthcare Sector Average
AMRN
Amarin
14.07
-1.58
-10.10%
AKBA
Akebia Therapeutics
0.87
-2.38
-73.17%
CAPR
Capricor Therapeutics
6.65
-1.31
-16.46%
TENX
Tenax Therapeutics
1.80
-4.17
-69.85%
PROK
ProKidney
1.33
-1.03
-43.64%
Amarin Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Amarin Shareholders Reject Dilution, Governance Proposals at AGM
Negative
May 15, 2026
At its May 13, 2026 annual general meeting, Amarin shareholders rejected proposals to expand the board’s authority to issue new shares, increase the 2020 Stock Incentive Plan, disapply U.K. pre‑emption rights, and shift to electronic d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.